09:52 AM EST - Nuvo Research Inc. : Announced the results of its investigational Phase 2 clinical trial of WF10 (Trial) for the treatment of allergic rhinitis. Patients dosed with WF10 did not report a reduction in symptoms that was significantly better than patients dosed with a saline placebo at any of the endpoints being measured in the study. Nuvo Research Inc.
shares T.NRI are trading down $0.82 at $5.52.
